This week we have been following the latest preclinical early stage clinical data coming out of the EORTC-NCI-AACR ENA Triple meeting in the beautiful city of Barcelona in Spain.

One presentation in particular on the art and science of overcoming T cell exhaustion with an intriguing and novel immunotherapy approach caught our attention.

What’s special or different about this particular immunotherapy and why does it stand out from the increasingly very competitive IO crowd?

Curious to learn more?

To continue reading our latest review and discussion of oncology new product development plus expert commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by